Cerus (CERS +2.8%) says the FDA has accepted its proposed modular Premarket Approval application...

|About: Cerus Corporation (CERS)|By:, SA News Editor

Cerus (CERS +2.8%) says the FDA has accepted its proposed modular Premarket Approval application shell - an outline of the application process defining the structure, content and timing of each module - for review of its Intercept Blood System for plasma. The agency's approval of a shell was required prior to initiation of a modular PMA submission, thus enabling CERS to proceed with an application that addresses multiple indications of plasma use for the system.